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ABSTRACT 
Acute hyperglycaemia and chronic hypertension worsen stroke outcome but their 
impact on collateral perfusion, a determinant of penumbral life span, is poorly 
understood.   Laser-speckle contrast imaging (LSCI) was used to determine the 
influence of these stroke  comorbidities on cortical perfusion after permanent middle 
cerebral artery occlusion (pMCAO) in Spontaneously Hypertensive Stroke Prone rats 
(SHRSP) and normotensive Wistar rats.  Four independent studies were conducted. In 
animals without pMCAO, cortical perfusion remained stable over 180 minutes.  
Following pMCAO, cortical perfusion was markedly reduced at 30 minutes then 
gradually increased, via cortical collaterals, over the subsequent 3.5 hours. In the 
contralateral non-ischaemic hemisphere perfusion did not change over time.  Acute 
hyperglycaemia (in normotensive Wistar) and chronic hypertension (SHRSP) attenuated 
the restoration of cortical perfusion after pMCAO. Inhaled nitric oxide did not influence 
cortical perfusion in SHRSP following pMCAO.   Thus, hyperglycaemia at the time of 
arterial occlusion or pre-existing hypertension impaired the dynamic recruitment of 
cortical collaterals after pMCAO.  The impairment of collateral recruitment may 
contribute to the detrimental effects these comorbidities have on stroke outcome. 
Keywords: Acute hyperglycaemia, cortical collateral perfusion, hypertension, 
ischaemic stroke, laser speckle contrast imaging. 
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INTRODUCTION 
Stroke is a leading cause of permanent disability and accounts for approximately 12% 
of all deaths in the world each year.1  Ischaemic stroke, caused by an occlusion of a 
cerebral blood vessel, represents 85% of all cases.2  The established treatments for 
ischaemic stroke are recanalisation of the occluded artery in order to allow reperfusion 
of the downstream territory:  thrombolysis with recombinant tissue plasminogen 
activator (r-tPA) or endovascular thrombectomy.3,4,5,6,7  However, only  a small 
proportion of stroke patients are eligible for these therapies due to a narrow therapeutic 
time window (<4.5 h for rt-PA & <6 h for thrombectomy) and risk of bleeding.8   
Following ischaemic stroke, the cerebral collateral circulation, a network of 
anastomoses between cerebral arteries, helps to maintain cerebral blood flow (CBF).9,10 
Leptomeningeal anastomoses (LMAs) are a network of pial arterioles that make 
connections between the middle, anterior and posterior cerebral arteries.  They provide a 
means of blood flow recruitment to the cortical layers of an occluded arterial territory.11 
These blood vessels dilate in response to a variety of direct neural, metabolic and 
haemodynamic factors.12 However, the primary factor that determines the direction of 
flow is the fall in hydrodynamic pressure at the distal ends of the affected major arteries.  
Effective collateral blood flow recruitment is known to extend the survival time of the 
injured, hypoperfused and potentially salvageable ischaemic penumbra as well as 
improve outcome following recanalisation therapies.12,13,14  Likewise, preclinical 
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evidence suggests that the quantity and dimension of LMAs is inversely related to 
neuronal death following stroke.15  The extent of collateral flow may explain the 
considerable number of patients that maintain a small ischaemic core and a significant 
penumbra beyond six hours and for up to several days following symptom onset16,17 
while other patients have aggravated brain tissue death and enlarged ischaemic 
core.17,18,19,20  
Established stroke co-morbidities (i.e. hypertension & acute hyperglycaemia) are 
associated with worse outcome following stroke.21,22,23 There is a paucity of information 
on the impact of stroke co-morbidities on the dynamics of cortical collateral recruitment 
during the first hours post-stroke.  Understanding the dynamics of collateral recruitment 
to support the ischaemic penumbra until CBF through the occluded artery is restored, 
may drive the development of new adjunct therapies.  Hence, to study the evolution of 
collateral perfusion after ischaemic stroke we used a rat permanent middle cerebral 
artery occlusion (pMCAO) model, and Laser speckle contrast imaging (LSCI), which 
combines high temporal and spatial resolution, to quantify relative CBF24.       
The principal aims were to characterise the dynamic changes in cortical collateral 
perfusion during the first critical hours following pMCAO, the influence of known 
stroke risk factors (acute hyperglycaemia and hypertension) and the impact of a 
potential therapeutic, inhaled nitric oxide (iNO) to enhance the recruitment of collateral 
perfusion.   
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METHODS 
Animals and study groups 
A. A total of sixty-five male rats (Wistar, n=38 and spontaneously hypertensive 
stroke-prone rat (SHRSP), n=27; 300-365 g) were randomly allocated to study and 
treatment groups according to specific aims, using random.org in four separate 
studies: A. To determine the dynamic changes in cortical perfusion following 
stroke (Wistar rats): Control (n=6) and pMCAO (n=10). 
B. To determine the influence of acute hyperglycaemia on cortical perfusion: 
pMCAO+vehicle (Wistar, n=11) and pMCAO+glucose (Wistar, n=11). 
C. To characterise the impact of chronic hypertension on the dynamic recruitment of 
collateral perfusion in SHRSP (pMCAO, n=9). 
D. To determine if iNO enhances the recruitment of cortical collateral perfusion in the 
presence of chronic hypertension: pMCAO+Air (SHRSP, n=9) and pMCAO+iNO 
(SHRSP, n=9). 
 
Wistar rats were purchased from Charles River and the SHRSPs were bred in a colony 
maintained at the Institute of Cardiovascular and Medical Sciences, University of 
Glasgow.  All rats were maintained in identical housing conditions: strain and age-
matched groups of four rats per cage, standard 12 h light-dark cycle along with 
unlimited access to water and chow.  A minimum of one week from date of delivery 
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was allowed for acclimatisation.  For study B (hyperglycaemia), rats were restricted to 
two chow pellets overnight for 15-17 h prior to experimentation.  This was to ensure 
baseline normoglycaemia (blood glucose concentration of 2.6-5.3 mmol/L in rats.25) 
under general anaesthesia.  All animal procedures were approved by the University of 
Glasgow Ethical Review Panel and performed under the UK Home Office Project 
Licences, 60/4449 and P643E89D8 for Preclinical Stroke and Experimental MRI and 
subject to the Animals (Scientific Procedures) Act of 1986 incorporating European 
Directive 2010/63/EU.  Experiments were carried out according to ARRIVE guidelines 
(http://www.nc3rs.org.uk/arrive-guidelines) during planning, experimentation, analysis 
and documentation of all procedures.   
 
Anaesthesia  
Using aseptic surgical technique, anaesthesia was induced (5% isoflurane) and, 
following oral intubation, maintained (2-3% isoflurane) during surgical preparation 
with artificial ventilation in a mixture of air:oxygen (1 L/min air, 0.2 L/min O2).  To 
reduce tracheal secretions and pain, atropine sulphate (0.05 mg/kg, s.c.) and 
ropivacaine hydrochloride (Norapin®; 0.2 ml s.c.) were administered over the abdomen 
and calvaria (site of cranial incision), respectively.  Following completion of surgical 
procedures, isoflurane was reduced to 1% and then gradually turned off during a bolus 
(80 mg/kg i.v.) and then continuous infusion (30 mg/kg/hr i.v.) of alpha-chloralose 
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(AC) for imaging and to maintain cerebral autoregulation and neurovascular coupling.  
Body temperature was maintained at 37±0.5 ºC and blood pressure, arterial blood gases 
(PaO2, PaCO2), blood pH and glucose were monitored throughout the experimental 
protocol.    
 
Middle cerebral artery occlusion & imaging window 
Rats were placed in a stereotaxic frame for skull thinning prior to induction of MCAO.  
The entire cortical surface was thinned using a dental drill, ensuring that the dura was 
left intact.  Rats were removed from the stereotaxic frame for induction of pMCAO 
which employed a minor modification of the intraluminal filament model of Koizumi 
et al.26  Briefly, permanent ligatures (4-0 sutures) were placed at the proximal portion 
of the CCA, external carotid, occipital and pterygopalatine arteries. A 4-0 nylon 
silicone coated tip monofilament (404134PK10 and 50-3033PKRe for Wistar and 
SHRSP rats; Doccol Corporation, MA, USA) was inserted into the CCA and gently 
advanced until resistance was felt, indicating occlusion at the origin of the middle 
cerebral artery (MCA).  The non-stroke control group received similar anaesthetic 
treatments for equivalent duration as well as calvaria thinning.  
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Induction of acute hyperglycaemia  
Rats were randomly allocated to receive either vehicle (saline) or glucose (15%; 10 
ml/kg) administered i.p. 10min prior to pMCAO, as previously described.23  Blood 
glucose levels were measured at baseline and at multiple time points following 
pMCAO using a glucometer (Accu-Check).  
 
Laser speckle contrast imaging (LSCI) and analysis 
Following the induction of pMCAO, rats were returned to the stereotaxic frame with 
their heads secured by tooth and ear bars to avoid movement artefact while imaging.  
Paraffin oil (JOHNSON’S® baby oil, USA) was applied to the surface of the thinned 
skull to ensure a stable signal during imaging.  Real time changes in cortical blood flow 
were recorded by means of a Laser speckle contrast imager (PeriCam PSI HD system, 
Perimed, Stockholm, Sweden), acquired from the estimation of intravascular red blood 
cell movement from a stack of images following 6 ms exposure time and programmed 
to produce 9 pixels (3x3) for contrast calculation. 
Perfusion values are calculated as ((1/C) -1)), where C is the contrast.  The penetration 
depth of the laser (785 nm) is approximately 500 µm below the thinned skull ensuring 
imaging of the cortical vessels on the brain surface. Temporal resolution was set at an 
effective frame rate of 0.2 images/second (averaging 5 images) with a spatial resolution 
of 20 µm.  A minimum stabilisation period of 10min was allowed under the laser 
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speckle contrast imager, before baseline recording commenced at 30 min from the onset 
of stroke, and continued until 4h post-MCAO.   
Cortical blood flow data for each rat were processed and extracted using PIMSoft 
(Perimed, Stockholm, Sweden).  Regions of interest (ROIs) were established at 30min 
post-MCAO (baseline) based on the following blood flow thresholds:27,28,29 ischaemic 
core (<43% of mean contralateral hemisphere); hypoperfused tissue (CBF between 43-
75% of mean contralateral hemisphere) along with contralateral equivalent ROIs as 
shown in Figure 1C.  For the control group, the entire ipsilateral and contralateral 
hemispheres were taken as the ROIs.  Blood flow data from each ROI were normalised 
to the respective mean blood flow during the first 10min at baseline (30 min post-
MCAO).   
 
Delivery of inhaled nitric oxide   
To determine if iNO can increase collateral flow in SHRSP, rats were randomised to 
receive either Air or iNO (60 ppm) starting at 30 min post-MCAO.  Nitric oxide (NO) 
gas was delivered in the ventilatory gas mixture and the concentrations of NO2 and O2 
were monitored and controlled using the INOMAX monitoring system (USA).  NO2 
concentration was maintained below 1.2 ppm, a level assumed to be toxic to the 
lungs,30 for the duration of the experiments. 
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Blinding and statistical analysis 
The experimenter was blind to group identity during data analysis for studies A, B and 
D as well as group identity during surgery & induction of hyperglycaemia for study B.  
All data were analysed using Graphpad Prism 6 (GraphPad Software, USA) and are 
presented as mean±SD. Mean normalised blood flow and mean arterial blood pressure 
(MABP) data were collected every 10min for statistical analysis.  To determine 
differences in blood flow within tissue compartments, area under curve for each ROI 
was calculated.  Unpaired Student’s t-test, multiple comparison 1-way ANOVA 
followed by Dunett’s test or repeated measures 2-way ANOVA followed by Sidak’s 
test were used to test the statistical significance of differences between groups, set at 
p<0.05.   
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RESULTS  
Dynamic recruitment of cortical perfusion following pMCAO 
Real time changes in cortical perfusion during the first hours following pMCAO were 
assessed in normotensive Wistar rats and compared with control non-stroke Wistar 
rats.  Physiological variables were stable throughout the experimental protocol with no 
significant differences between groups (F(2,28)=0.1049, p=0.9008 for pH, F=0.08536, 
p=0.9184 for PaO2, F=2.123, p=0.1385 for PaCO2 and F=1.881, p=0.1712 for body 
temperature. Supplemental Table 1). 
 
Cortical perfusion within the ischaemic core in the pMCAO group increased by 
215±131% by 2.5h post-MCAO when compared to baseline (30 min pMCAO, Figure 
2B).  Cortical perfusion within the hypoperfused ROI also increased over the time 
course (170±97%).  This increase in perfusion within the ischaemic core and 
hypoperfused regions was significantly different compared to perfusion data for the 
equivalent contralateral ROIs (F(2,23)=5.763, p=0.0094;  Figure 2C).  No significant 
increase in cortical perfusion was observed within these ROIs (19±5% for ischaemic 
core and 19±7% for hypoperfused ROIs, respectively, F(2,23)=1.439, p=0.2578, 
Figure 2D and 2E) indicating that this increase in blood flow is specific to the 
ischaemic hemisphere.  Importantly, no significant change (F(13,182)=0.8987, 
p=0.5556) in mean arterial blood pressure (MABP) was observed over the duration of 
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the experimental protocol indicating that the increase in blood flow was not driven by 
changes in systemic blood pressure (Figure 2F).  The increase in ipsilateral cortical 
blood flow originated from the midline, at the boundary of the initial blood flow 
deficit, moving towards the ischaemic core.  This suggests the recruitment of cortical 
collateral vessels (leptomeningeal anastomoses) rather than an increase in flow through 
the occluded MCA (see 2nd row of Figure 2A).  In control non-stroke rats, there was no 
change in blood flow over the same time course (1st row of Figure 2A).   
 
Impact of acute post-stroke hyperglycaemia on cortical perfusion  
Real time changes in cortical perfusion were assessed in a model of acute 
hyperglycaemia following pMCAO in normotensive rats and vehicle-treated control 
rats.  Physiological variables were within reference ranges throughout the experimental 
protocol with no significant differences between groups (F(4,80)=1.642, p=0.1279 for 
pH, F=0.5482, p=0.7009 for PaO2, F=1.077, p=0.3887 for PaCO2 and F=1.054, 
p=0.346 for body temperature, Supplemental Table 2).  Blood glucose concentration 
was significantly higher (F(5,120)=20.28, p=0.0001) at all time points with peak 
values at 30min post-MCAO for pMCAO+glucose rats when compared to 
pMCAO+vehicle group (Figure 3K).  This confirmed successful induction and 
maintenance of a clinically relevant level of acute hyperglycaemia.   
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Cortical perfusion within the ischaemic core increased by 212±80% and 78±11% in the 
pMCAO+vehicle and pMCAO+glucose groups, respectively, by 4h post-MCAO when 
compared to baseline (Figure 3B).  The increase in cortical perfusion within the 
ischaemic core of normoglycaemic rats was significantly attenuated in the presence of 
hyperglycaemia (t, df=2.530,11, p=0.0280, Figure 3C).  A similar increase in cortical 
perfusion was observed over the time course in the hypoperfused ROI in the 
pMCAO+vehicle group (156±71%) and this increase was attenuated in the 
pMCAO+glucose treated rats (82±10%, Figure 3D).  The difference between groups 
did not achieve statistical significance (t,df=1.468, 18, p=0.1593, Figure 3E).  In the 
contralateral hemisphere there was a small change in cortical perfusion within the 
homotopic contralateral ischaemic core ROI over the time course in both groups 
(change in perfusion: contralateral to ischaemic core, 35±43% vs 3±7% for vehicle and 
glucose groups, respectively, Figure 3F).  A similar change in cortical perfusion was 
observed within the homotopic contralateral hypoperfused ROI (change in perfusion: 
30±58% vs 5±6% for vehicle and glucose groups, respectively, Figure 3H).  Within the 
contralateral hemisphere the small increase in perfusion in both ROIs in the 
normoglycaemic group was significantly attenuated in the hyperglycaemic group (t,df= 
2.975, 11, p=0.0126 and t,df=2.324, 18, p=0.0320, respectively. Figure 3G and 3I).  No 
significant change (F(17,360)=0.9064, p=0.5667) in MABP was observed over the 
duration of the experimental protocol (Figure 3J), indicating that blood pressure did not 
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influence the impaired recruitment of cortical collateral blood vessels in the 
pMCAO+glucose group when compared to pMCAO+vehicle (Figure 3A). 
 
Impact of chronic hypertension on cortical perfusion following pMCAO 
Physiological variables in SHRSP were within reference ranges throughout the 
experimental protocol (Supplemental Table 3).  There was no significant change in 
cortical perfusion within the ipsilateral hemisphere of SHRSPs throughout the time 
course (change in perfusion from baseline to 4h:  5±23% & 5±19% for the ischaemic 
core and hypoperfused ROIs, respectively; Figure 4B and 4D).  Similarly, there was no 
change in cortical perfusion throughout the time course in the contralateral ROIs 
(change in perfusion from baseline to 4h:  10±10% and 10±9% for the contralateral 
ischaemic core and hypoperfused ROIs, respectively; Figure 4B and 4D).  The 
recruitment of cortical collateral blood vessels was impaired (Figure 4A) despite stable 
MABP observed throughout the experimental protocol (Figure 4F). 
 
Investigation of the potential of intervention to enhance blood flow following 
pMCAO 
The effect of iNO (at 60ppm) on cortical perfusion was measured following pMCAO 
in SHRSP and compared to control SHRSP that received air only.  Figure 5A shows an 
example perfusion map from the median animal from each group over time.  
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Physiological variables were within reference ranges throughout the experimental 
protocol with no significant differences between groups (F(3,48)=0.8152, p=0.4978 for 
pH, F=0.4128, p=0.7410 for PaO2, F=0.2249, p=0.8786 for PaCO2 and F=1.127, 
p=0.3474 for body temperature. Supplemental Table 4).  For both groups, arterial 
blood glucose concentration was slightly raised (>6mmol/L) 10min prior to the 
induction of pMCAO but returned to the normal range (3.5≥6mmol/L) from 1h post-
MCAO until the end of experimental protocol (see Figure 5K).  No significant 
differences were observed between groups throughout the protocol.   
 
There was no significant difference in cortical perfusion between iNO and vehicle-
treated rats in the ischaemic core (change in perfusion from baseline to 4hr pMCAO:  
16±14% vs 8±1% for air & iNO groups, respectively) and hypoperfused ROIs 
(10±20% vs 4±2% for air & iNO groups, respectively. Figure 5B & D).  Area under 
the curve analysis confirmed that there were no differences in cortical perfusion over 
time and between treatment groups (Figure 5C & E).  Within the contralateral 
equivalent ROIs there was no change in cortical perfusion over time and between 
treatment groups (Figures 5G& I).   
Stable MABP was observed over the duration of the experimental protocol with no 
significant difference between groups (F (20, 320)=0.5966, p=0.9146, Figure 5J), 
indicating that iNO did not alter MABP.   
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DISCUSSION  
The present study demonstrates, for the first time, the dynamic recruitment of cortical 
collateral perfusion during the first critical hours following experimental stroke in rat 
models with and without known stroke risk factors.  LSCI revealed stable, cortical flow 
over the duration of imaging (4h) in non-stroke control Wistar rats.  Following cortical 
ischaemia induced by pMCAO, cortical collateral perfusion gradually increases within 
the ischaemic hemisphere.  In contrast, the presence of clinically relevant levels of 
acute post-stroke hyperglycaemia results in a significant attenuation in the recruitment 
of cortical collateral perfusion.  Similarly, rats with chronic hypertension (SHRSP) 
demonstrate a failure of cortical collateral perfusion recruitment after pMCAO.  
Finally, we found that iNO did not ameliorate the failed recruitment of cortical 
collateral perfusion demonstrated in SHRSP following pMCAO. 
 
LSCI acquires perfusion data from the estimation of intravascular red blood cell 
movement from a stack of images24.  LSCI therefore provides real time full-field 
imaging with robust temporal and spatial resolution suitable for the dynamic 
quantification of blood flow in the vasculature of the cortex.  The benefits of LSCI 
include a relatively faster signal processing time and near real-time blood flow 
estimates for the semi-invasive investigation of blood flow dynamics with excellent 
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reproducibility when compared to other optical and non-optical imaging 
systems.31,32,33,24 However, LSCI also presents some limitations which include: 
distortion of the overall estimates by static artefacts76 as well as shallow penetration of 
the laser rays which requires the surgical removal or thinining of the cavaria for rat 
cerebral studies.24  Also, LSCI data cannot be used to directly compare between 
animals or timepoints without data normalisation.  This is because LSCI does not 
provide absolute perfusion values owing to the undefined mathematical relationship 
between speckle contrast and blood flow velocity.71,72  
 
Regarding collateral perfusion following stroke, increased cortical perfusion was 
detected in the ipsilateral ischaemic core and hypoperfused ROIs during the first 3-4 
hours following pMCAO in two separate groups of rats (normotensive and 
normoglycaemic animals in studies A & B) and importantly, was specific to the 
ischaemic hemisphere since no significant changes in perfusion were observed within 
the contralateral hemisphere of these animals or in non-stroke control rats.  The 
increased perfusion in the ischaemic territory is likely to reflect the recruitment of 
collateral vessels lying close to the midline, and adjacent to the cerebral region known 
to be supplied by the anterior cerebral artery (ACA) in rats.  The increase in collateral 
perfusion following pMCAO is a compensatory mechanism to redirect blood supply to 
the ischaemic region in order to maintain blood flow and potentially salvage the 
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ischaemic penumbra.33 These observations support and extend earlier studies of 
collateral flow.  Ten minutes following pMCAO, Strong et al.34 reported an 
approximate 50-70% increase in CBF in the core and hypoperfused regions of the 
gyrencephalic cortex in cats.  The blood flow recovery was near pre-occlusion values 
by 90min post-MCAO.  Similarly, a variable recruitment of collateral perfusion has 
been reported in normotensive and normoglycaemic rats where anastomotic 
connections between ACA and MCA were observed following the induction of 
MCAO.  In an embolic MCAO model in Sprague-Dawley rats, Armitage et al.35 
reported an immediate anastomotic connection established between the branches of 
ACA and MCA which persisted for up to 24h.  In a different study, these anastomotic 
connections following pMCAO in Sprague-Dawley rats were classified into three 
categories, viz: transient, impermanent and persistent, based on their dynamic 
evolution 3h following recruitment.36 Also, cortical vessel recruitment following 
ischaemic stroke has been reported in humans.37,38   
 
Changes in vascular physiology (MABP, blood pH, PaO2 and PaCO2) due to 
anaesthesia may potentially impact on cerebral blood flow.  Hence, all rats were 
mechanically ventilated to prevent respiratory depression and AC anaesthesia chosen 
for the LSCI session to limit anaesthesia effects on vascular physiology and cerebral 
blood flow.39,40  PaCO2 in particular  is known to dilate cerebral vessels and increase 
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CBF.41,42  Therefore, for all study groups and treatments, blood physiological 
parameters (PaCO2, PaO2, and pH) and body temperature were monitored and 
maintained within the normal range.  Small differences in MABP between groups were 
not statistically significant.  Therefore, differences in physiological parameters were 
not responsible for the observed changes in the recruitment of collateral perfusion 
following pMCAO.   
 
The physiological recruitment of collaterals following pMCAO was impaired in our rat 
model of acute hyperglycaemia.  This may explain, in part at least, our previous report 
of more rapid growth of ischaemic brain lesions, as determined by diffusion-weighted 
MRI, following pMCAO in acute hyperglycaemic rats compared to normoglycaemic 
controls.23  It is also consistent with patient studies linking acute hyperglycaemia 
(defined as sustained blood glucose concentration above 6.0 mmol/L), with poorer 
functional outcome and higher mortality following stroke.47,48,49,50,51,52,53,54   Further, a 
recent study55 showed that hyperglycaemia in stroke patients with good collaterals 
decreases clinical prognosis and had no effect on patients with poor collateral 
recruitment.  This suggests that high blood glucose around the time of stroke is 
detrimental to neurological recovery in stroke patients with otherwise functional 
collateral capacity.   
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In a recent rat study, our group assessed the influence of acute hyperglycaemia on 
cerebral blood flow after pMCAO using alternative CBF methods.  Using in vivo 
autoradiography and perfusion-weighted MRI there was no detectable  effect of this 
level of hyperglycaemia on CBF, although ischaemic brain damage was increased.56  
These seemingly contradictory findings may reflect the different sensitivities of 
autoradiography and MRI versus LSCI with the latter providing a more sensitive 
method of assessing changes in cerebral perfusion.  The pathophysiological mechanism 
for the impaired recruitment of collateral flow in acute post-stroke hyperglycaemia is 
not yet clear.  However, raised blood glucose concentration is known to inhibit NO-
mediated vasodilatation, partly due to an induced decrease in NO bioavailability.57,58  
Another important factor that has been suggested is hyperglycaemia-induced blood 
coagulation and fibrinolysis dysfunction leading to increased blood viscosity and 
impaired erythrocyte functions.59  
 
Hypertension is an important risk factor for stroke which also worsens functional 
outcome in humans.60,61  Owing to the spontaneous development of essential 
hypertension (~220mmHg systolic) and stroke, SHRSPs represent one of the most 
clinically relevant rat models of chronic hypertension in pre-clinical research.62,63  The 
genetically related spontaneously hypertensive rat (SHR, ~180mmHg systolic), which 
rarely shows signs of spontaneous stroke, is also widely used64,65.   
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Our observation of the impaired recruitment of collateral flow in the SHRSP is 
consistent with a previous report.66  Coyle and Heistad66 quantified the anastomoses 
between the ACA and MCA in the normotensive control Wistar Kyoto strain (WKY) 
and SHRSP.  They showed no reduction in the number of anastomoses but a 
considerable narrowing of the collateral anastomoses in SHRSP compared to WKY and 
following MCAO.  When compared to WKY, we and others have also reported an 
increased sensitivity of SHRSP to stroke67,68,69 as well as the rapid infarction of the 
penumbral tissue apparent within 1h following pMCAO.21,22  Hypertension is associated 
with  vasoconstriction in cerebral vessels and decreased vasorelaxation.  The ex vivo 
study of Chan et al.70 showed luminal constriction of LMAs isolated from young (18 
weeks old) and aged (48 weeks old) SHR when compared to normotensive WKYs.  
Also, the study reported that small intraluminal pressure stimulation of 20 mmHg 
resulted in more constriction of LMAs from young SHR when compared with aged 
SHRs.  Recently, using multisite laser doppler flowmetry, further studies from the same 
group64,65 reported poor collateral perfusion during 2 h transient MCAO in aged and 
young SHRs. These findings of collateral failure in SHR are in agreement with the 
results of the present studies in SHRSP and provide evidence for beneficial effects of 
oxygen-based therapy     and PAI-1 inhibition on collateral function.71  
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 Increased glutamate concetnration,72 and the increased levels of the  powerful 
vasoconstrictor, 20-HETE, in the brain of SHRSPs following ischaemic stroke73 may 
also contribute to the impairment of cortical collateral flow.  Dunn et al. 73 showed that 
the suppression of 20-HETE with intracerebral injection of HET-0016, a potent 
inhibitor of 20-HETE, reduced infarct volume following stroke.  However, iNO at 
60ppm, a potent vasodilator shown to selectively dilate cerebral blood vessels in the 
ischaemic territory of normotensive mice,74  did not ameliorate the impaired recruitment 
of collateral perfusion in the SHRSP, in our hands, following pMCAO. 
 
Taken together the data reported here demonstrate that hypertension or acute post-
stroke hyperglycaemia impair the recruitment of collateral perfusion following 
ischaemic stroke in rats.  These findings provide insight into the rapid evolution of 
brain damage and decreased volume of salvageable brain tissue, as well as the 
aggravated outcome following stroke in the presence of these comorbidities, and 
provide an experimental platform to test therapies designed to support penumbra until 
reperfusion is induced.  In addition to age, hyperuricaemia and metabolic syndrome 
have also been associated with poor collateral status in human stroke patients.54  
Hence, in the continuous quest for effective collateral flow enhancers, these stroke 
comorbidities should also  be considered. This study is subject to some limitations.  
Firstly, we did not carry out statistical power calculation a priori to determine group 
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size.  Secondly, we did not include a normotensive strain for our SHRSP group in 
study C, and lastly, we did not assess infarct or lesion volume.  The paper presents an 
exploratory insight to the potential of LSCI to study collateral recruitment and how the 
contributors of worsened stroke outcome (chronic hypertension and acute 
hyperglycaemia) influence the recruitment of collateral perfusion following stroke.  
UK animal regulation does not permit recovery of animals under prolonged AC 
anaesthesia. 
 
In conclusion, we present novel longitudinal in vivo data demonstrating significantly 
attenuated cortical collateral perfusion in the presence of known risk factors such as 
acute post-stroke hyperglycaemia and chronic hypertension.  This impaired recruitment 
of collateral perfusion may in part explain the worse outcome and accelerated growth 
of brain damage in the presence of these risk factors.  In addition, we have shown that 
inhaled NO does not enhance collateral perfusion following stroke in a rat model with 
pre-existing hypertension.  In agreement with previous reports75,76,77 we show that 
LSCI is an effective tool to investigate cortical blood flow changes following pre-
clinical treatments or experimental manipulations in vivo.  In combination with animal 
models of stroke comorbidities LSCI promises to be a robust tool in the development 
of vasodilators or cerebral blood flow enhancers and the evaluation of their real time 
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cerebrovascular effects in the setting of preclinical stroke and other neurovascular 
applications.  
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FIGURE LEGENDS 
Figure 1.  Laser speckle contrast imaging set up and analysis. (A) A representative 
laser speckle image showing normally perfused rat brain with superior cortical vessels 
before pMCAO was induced.  (B) A representative laser speckle image of the cortical 
surface following pMCAO, showing normal blood flow in the contralateral hemisphere 
(red-yellow) and cortical blood flow deficit in the ipsilateral hemisphere (blue-black).  
(C) Regions of interest (ROIs) on the LSCI defined with applied CBF thresholds: 
ischaemic core (cortical blood flow <43% of mean contralateral hemisphere), 
hypoperfused tissue (cortical blood flow between 43-75% of mean contralateral 
hemisphere) along with contralateral equivalent ROIs. 
 
Figure 2.  Recruitment of cortical collateral blood flow post-MCAO. (A) Cortical 
blood flow map of a representative rat per group.  (B) Increase in cortical blood flow in 
the ROIs of the ipsilateral hemisphere following pMCAO while blood flow remained 
relatively unchanged in the non-stroke control group over time.  Cortical blood flow 
values for each ROI were normalised to their respective 10min average at baseline and 
the entire ipsilateral hemisphere was the ROI for non-stroke controls.  (C) Area under 
curve of cortical perfusion in the ipsilateral hemisphere ROIs  used to test the statistical 
difference between groups over the time course of ischaemia (0.5-4h) and  analysed 
using Student’s unpaired t-test, p>0.05*.  (D) Cortical blood flow was unchanged from 
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baseline in all equivalent ROIs in the contralateral hemisphere.  (E) Area under curve 
for cortical perfusion in the contralateral hemisphere ROIs, over the time course of 
ischaemia.  (F) No significant change in MABP over the time course of the 
experiment.  Area under curve data for cortical perfusion presented as mean ± SD, 
other data presented as mean + SD.  
 
Figure 3.  Impact of acute hyperglycaemia on cortical collateral blood flow. (A) 
Cortical blood flow map of a representative rat per group.  (B) Cortical blood flow in 
the ipsilateral ischaemic core ROI. (C) Area under curve for cortical perfusion (0.5-4h) 
in the ipsilateral ischaemic core ROI of vehicle and glucose groups, p>0.05*.  (D) 
Cortical blood flow in the ipsilateral hypoperfused ROI.  (E). Area under curve of 
cortical perfusion (0.5-4h) in the ipsilateral hypoperfused ROI.  (F) Cortical perfusion 
in the ROI contralateral to ischaemic core.  (G) Area under curve of cortical perfusion 
in the ROI contralateral to ischaemic core, p>0.05*.  (H) Cortical perfusion in the ROI 
contralateral to the hypoperfused ROI.  (I) Area under curve of cortical perfusion in the 
ROI contralateral to the  hypoperfused ROI, p>0.05*.  (J) MABP, stable over the time 
course of ischaemia, in vehicle and glucose groups.  (K) Blood glucose concentration 
10min prior to and during the time course of ischaemia.  Analysed using repeated 
measures 2way ANOVA, p=0.0001*.  Area under curve data for cortical perfusion 
presented as mean ± SD, other data presented as mean + SD. 
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Figure 4.  Impact of chronic hypertension on cortical collateral blood flow.  (A) 
Cortical blood flow map of a representative SHRSP rat following pMCAO.  (B) 
Cortical blood flow normalised to the respective 10min average at baseline in the 
ipsilateral ischaemic core and equivalent contralateral ROI.  (C) Area under curve of 
cortical perfusion in the ipsilateral ischaemic core and equivalent contralateral ROI, 
over the time course of ischaemia (0.5-4h), analysed using Student’s unpaired t-test, 
p>0.05*.  (D) Cortical blood flow, normalised to the respective 10min average at 
baseline, in hypoperfused ROI and equivalent contralateral ROI.  (E) Area under curve 
of cortical perfusion for hypoperfused ROI and equivalent contralateral ROI.  (F) 
MABP data over the time course of ischaemia.  Area under curve data for cortical 
perfusion presented as mean ± SD, other data presented as mean + SD.  
 
Figure 5. Influence of iNO on cortical collateral recruitment post-MCAO.  (A) 
Cortical blood flow map for representative rat per group over the time course of 
ischaemia.  (B) Cortical blood flow, normalised to the respective 10min average at 
baseline,in the ipsilateral ischaemic core ROI.  (C) Area under curve of cortical 
perfusion in the ipsilateral ischaemic core ROI over the time course of ischaemia (0.5-
4h).  (D) Cortical blood flow, normalised to the respective 10min average at baseline, 
in the ipsilateral hypoperfused ROI.  (E) Area under curve for cortical perfusion in the 
ipsilateral hypoperfused ROI.  (F) Cortical perfusion, normalised to the respective 
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10min average at baseline, in the ROI contralateral to ischaemic core.  (G) Area under 
curve of cortical perfusion for ROI contralateral to ischaemic core.  (H) Cortical 
perfusion, normalised to the respective 10min average at baseline, in the ROI 
contralateral to hypoperfused ROI.  (I) Area under curve of cortical perfusion for ROI 
contralateral to hypoperfused ROI.  (J) MABP over the time course of ischaemiain Air 
and iNO groups.  (K) Blood glucose concentration 10min prior to and during the time 
course of ischaemia.  Area under curve data for cortical perfusion presented as mean ± 
SD, other data presented as mean + SD. 
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Figure 1.  Laser speckle contrast imaging set up and analysis. (A) A representative laser speckle 
image showing normally perfused rat brain with superior cortical vessels before pMCAO was 
induced.  (B) A representative laser speckle image of the cortical surface following pMCAO, 
showing normal blood flow in the contralateral hemisphere (red-yellow) and cortical blood flow 
deficit in the ipsilateral hemisphere (blue-black).  (C) Regions of interest (ROIs) on the LSCI defined 
with applied CBF thresholds: ischaemic core (cortical blood flow <43% of mean contralateral 
hemisphere), hypoperfused tissue (cortical blood flow between 43-75% of mean contralateral 
hemisphere) along with contralateral equivalent ROIs. 
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Figure 2.  Recruitment of cortical collateral blood flow post-MCAO. (A) Cortical blood flow 
map of a representative rat per group.  (B) Increase in cortical blood flow in the ROIs of the 
ipsilateral hemisphere following pMCAO while blood flow remained relatively unchanged in the 
non-stroke control group over time.  Cortical blood flow values for each ROI were normalised to 
their respective 10min average at baseline and the entire ipsilateral hemisphere was the ROI for non-
stroke controls.  (C) Area under curve of cortical perfusion in the ipsilateral hemisphere ROIs  used 
to test the statistical difference between groups over the time course of ischaemia (0.5-4h) and  
analysed using Student’s unpaired t-test, p>0.05*.  (D) Cortical blood flow was unchanged from 
baseline in all equivalent ROIs in the contralateral hemisphere.  (E) Area under curve for cortical 
perfusion in the contralateral hemisphere ROIs, over the time course of ischaemia.  (F) No 
significant change in MABP over the time course of the experiment.  Area under curve data for 
cortical perfusion presented as mean ± SD, other data presented as mean + SD.  
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Figure 3.  Impact of acute hyperglycaemia on cortical collateral blood flow. (A) Cortical blood 
flow map of a representative rat per group.  (B) Cortical blood flow in the ipsilateral ischaemic core 
ROI. (C) Area under curve for cortical perfusion (0.5-4h) in the ipsilateral ischaemic core ROI of 
vehicle and glucose groups, p>0.05*.  (D) Cortical blood flow in the ipsilateral hypoperfused ROI.  
(E). Area under curve of cortical perfusion (0.5-4h) in the ipsilateral hypoperfused ROI.  (F) Cortical 
perfusion in the ROI contralateral to ischaemic core.  (G) Area under curve of cortical perfusion in 
the ROI contralateral to ischaemic core, p>0.05*.  (H) Cortical perfusion in the ROI contralateral to 
the hypoperfused ROI.  (I) Area under curve of cortical perfusion in the ROI contralateral to the  
hypoperfused ROI, p>0.05*.  (J) MABP, stable over the time course of ischaemia, in vehicle and 
glucose groups.  (K) Blood glucose concentration 10min prior to and during the time course of 
ischaemia.  Analysed using repeated measures 2way ANOVA, p=0.0001*.  Area under curve data 
for cortical perfusion presented as mean ± SD, other data presented as mean + SD. 
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Figure 4.  Impact of chronic hypertension on cortical collateral blood flow.  (A) Cortical blood 
flow map of a representative SHRSP rat following pMCAO.  (B) Cortical blood flow normalised to 
the respective 10min average at baseline in the ipsilateral ischaemic core and equivalent contralateral 
ROI.  (C) Area under curve of cortical perfusion in the ipsilateral ischaemic core and equivalent 
contralateral ROI, over the time course of ischaemia (0.5-4h), analysed using Student’s unpaired t-
test, p>0.05*.  (D) Cortical blood flow, normalised to the respective 10min average at baseline, in 
hypoperfused ROI and equivalent contralateral ROI.  (E) Area under curve of cortical perfusion for 
hypoperfused ROI and equivalent contralateral ROI.  (F) MABP data over the time course of 
ischaemia.  Area under curve data for cortical perfusion presented as mean ± SD, other data 
presented as mean + SD.  
 
 
 
 
 
 
 
 
 
 
 
5 
 
 
Figure 5. Influence of iNO on cortical collateral recruitment post-MCAO.  (A) Cortical blood 
flow map for representative rat per group over the time course of ischaemia.  (B) Cortical blood 
flow, normalised to the respective 10min average at baseline,in the ipsilateral ischaemic core ROI.  
(C) Area under curve of cortical perfusion in the ipsilateral ischaemic core ROI over the time course 
of ischaemia (0.5-4h).  (D) Cortical blood flow, normalised to the respective 10min average at 
baseline, in the ipsilateral hypoperfused ROI.  (E) Area under curve for cortical perfusion in the 
ipsilateral hypoperfused ROI.  (F) Cortical perfusion, normalised to the respective 10min average at 
baseline, in the ROI contralateral to ischaemic core.  (G) Area under curve of cortical perfusion for 
ROI contralateral to ischaemic core.  (H) Cortical perfusion, normalised to the respective 10min 
average at baseline, in the ROI contralateral to hypoperfused ROI.  (I) Area under curve of cortical 
perfusion for ROI contralateral to hypoperfused ROI.  (J) MABP over the time course of ischaemiain 
Air and iNO groups.  (K) Blood glucose concentration 10min prior to and during the time course of 
ischaemia.  Area under curve data for cortical perfusion presented as mean ± SD, other data 
presented as mean + SD. 
 
 
 
 
 
 
 
 
 
